About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medexus Pharmaceuticals Inc (TSX: MDP )

2.670 -0.010 (-0.37%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,460
Open 2.650
Bid (Size) 2.660 (1)
Ask (Size) 2.690 (12)
Prev. Close 2.680
Today's Range 2.570 - 2.680
52wk Range 1.440 - 3.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 million 
From Medexus Pharmaceuticals Inc
Via GlobeNewswire

Performance

YTD
+4.71%
+4.71%
1 Month
-0.37%
-0.37%
3 Month
+6.80%
+6.80%
6 Month
+67.92%
+67.92%
1 Year
-6.64%
-6.64%

More News

Read More
Medexus Announces New License Deal for Topical Terbinafine
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Earnings Scheduled For October 28, 2021
Via Benzinga
Medexus Announces US$58.5 million in New Credit Facilities
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Pharmaceuticals Inc. (TSX: MDP) (OTCQX: MEDXF) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
Medexus to Participate in 35th Annual Roth Conference
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Welcomes Two New Board Members
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Secures Public Reimbursement for Cuvposa® in Quebec
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Schedules Third Fiscal Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Schedules Second Quarter 2023 Conference Call
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount
From Medexus Pharmaceuticals Inc
Via GlobeNewswire
How To Pick Dividend-Payers, Plus My Favorite One To Buy Now
Via Talk Markets
Fitness App Hopes to Innovate, Keep Resolutions, by Paying To Complete a Workout Built for Your Level of Exercise
Via Benzinga
Sidoti December Micro Cap Virtual Conference
From Sidoti & Company, LLC
Via AccessWire
The Rise And Fall Of MySpace
Via Talk Markets
Paul Rudd Named People's Sexiest Man Alive For 2021
Via Benzinga
Making a Difference When You Invest? Medexus Says It Improves Lives
Via Benzinga
What Is IAC Planning With Its Acquisition of Magazine Publisher Meredith?
Via The Motley Fool
InvestorNewsBreaks – Nexstar Media Group Inc.’s (NASDAQ: NXST) Hartford-Based Station to Launch NEXTGEN TV
Via Investor Brand Network
5 Value Stocks In The Communication Services Sector
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.